Category: Research
Phase 1 Trial for New ILD Therapy Begins
The following is an excerpt from a press release by aTyr Pharma, Inc detailing their new study focusing on a potential therapy for treating interstitial lung diseases: SAN DIEGO, Nov. 27, 2017 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics...
Study of ACZ885 (Canakinumab) in Patients with Pulmonary Sarcoidosis
The purpose of this study is to find out if the drug ACZ885 (Canakinumab) will improve lung function and also lower inflammation in patients with pulmonary sarcoidosis. This is a double blind study. This means neither participants nor researchers will know which...
Request for Applications: New Grant Period for FSR Clinical Studies Network
The application for this grant period is now closed. Learn more about the CSN. The FSR-CSN is a collaborative network of sites facilitating multi-site trials and studies in sarcoidosis research. The Network is focused on highly innovative projects with the intent of...Rare Disease Research Consortium Announces Ambitious Goals
FSR is excited to share some breaking news from the world of rare disease research that could have a huge impact on the future of diagnosing and treating rare diseases worldwide. The International Rare Diseases Research Consortium (IRDiRC) has released an ambitious...
Can Tracking Fitness Help Sarcoidosis Patients?
Tracking your fitness may be a way to help manage symptoms and side effects for sarcoidosis patients. As many sarc warriors know, it can be extremely difficult to stay active when you’re living with sarc. Between the chronic pain, fatigue, shortness of breath,...
Do You Know About Your Health Data?
Did you know, you have access to all of your health data online? 41% of Americans have never taken advantage of their ability to see this information, and 27% reported not even being aware they had the right to! We invite you to learn more about FasterCures’ new...
CLEAR Trial: Phase II Investigation of Antimycobacterial Therapy of Progressive, Pulmonary Sarcoidosis
The main purpose of this study is to investigate the efficacy and safety of oral antimycobacterial therapy in patients with confirmed progressive pulmonary sarcoidosis. CLEAR is an acronym used to describe treatment with Combination Levofloxacin, Ethambutol,...
Taking Steps Towards A Cure
If you were one of over 500 people worldwide who joined FSR for our annual K.I.S.S. 5K and virtual walks, you are part of the movement that will put sarcoidosis on the map – the same map as other big name diseases with national walk events that bring in millions...
Healthcare Innovation Under the New Administration
With the upcoming inauguration of the 45th President of the United States, the country is preparing for big changes, especially when it comes to healthcare. The potential repeal of the Affordable Care Act threatens some provisions for chronic and rare disease patients. For example, the ACA prohibited insurance companies from setting lifetime caps on medical expenses …